Comparative Study of Papaverine Plus Phentolamine Versus Prostaglandin E1 in Erectile Dysfunction
1997; Lippincott Williams & Wilkins; Volume: 157; Issue: 6 Linguagem: Inglês
10.1016/s0022-5347(01)64694-9
ISSN1527-3792
AutoresAntoine Bechara, Adolfo Casabé, G. Chéliz, Salomón Víctor Romano, H. Rey, Norberto M. Fredotovich,
Tópico(s)Genital Health and Disease
ResumoNo AccessJournal of UrologyClinical Urology: Original Article1 Jun 1997Comparative Study of Papaverine Plus Phentolamine Versus Prostaglandin E1 in Erectile Dysfunction A. Bechara, A. Casabe, G. Cheliz, S. Romano, H. Rey, and N. Fredotovich A. BecharaA. Bechara , A. CasabeA. Casabe , G. ChelizG. Cheliz , S. RomanoS. Romano , H. ReyH. Rey , and N. FredotovichN. Fredotovich View All Author Informationhttps://doi.org/10.1016/S0022-5347(01)64694-9AboutFull TextPDF ToolsAdd to favoritesDownload CitationsTrack CitationsPermissionsReprints ShareFacebookLinked InTwitterEmail Abstract Purpose: We compared the efficacy and short-term adverse effects of 1 ml. 30 mg./ml. papaverine plus 0.5 mg./ml. phentolamine versus 1 ml. 30 micro g./ml. prostaglandin E1 in patients undergoing pharmacological erection testing. Materials and Methods: A total of 60 patients (mean age 58 years) with a history of sexual erectile dysfunction longer than 6 months was randomly classified into 6 groups to be tested 1 week apart with the 2 solutions and with placebo to evaluate erection response and short-term adverse effects. Results: Of the patients tested with papaverine plus phentolamine 54% responded with erections adequate for penetration, compared to 50% of those tested with prostaglandin E1 (p >0.05). Prolonged erection occurred in 18% of patients tested with papaverine plus phentolamine and 15% of those tested with prostaglandin E1 (p >0.05). Pain was reported by 15 and 35% of patients, respectively (p <0.05). Conclusions: One ml. 30 mg./ml. papaverine plus 0.5 mg./ml. phentolamine has the same efficacy and equal prolonged erection rate as 1 ml. 30 micro g./ml. prostaglandin E1 but the latter agent induces significantly more pain. References 1 : Intracavernous injection of papaverine for erectile failure. Letter to the Editor. Lancet1982; 2: 938. Google Scholar 2 : Auto-injection of the corpus cavernosum with a vasoactive drug combination for vasculogenic impotence. J. Urol.1985; 133: 39. Link, Google Scholar 3 : Corpus cavernosum blockade for impotence: practical aspects and results in 250 cases. J. Urol.1986; 135: 206A. part 2, abstract 808. Google Scholar 4 : Intracavernous injection of prostaglandin E1 for the treatment of erectile impotence. J. Urol.1989; 141: 323. Link, Google Scholar 5 : Long term follow-up on self intracavernous injections (SICI) for impotence. J. Urol., part 21989; 141: 288A. abstract 476. Google Scholar 6 : Rescuing the failed papaverine/phentolamine erection: a proposed synergistic action of papaverine, phentolamine and prostaglandin E1. Int. J. Impotence Res.1990; 2: 277. Google Scholar 7 : Four-drug intracavernous therapy for impotence due to corporeal veno-occlusive dysfunction. J. Urol., part 21993; 149: 1291. Abstract, Google Scholar 8 : An improved vasoactive drug combination for a pharmacological erection program. J. Urol.1991; 146: 1564. Link, Google Scholar 9 : Pharmacotesting in erectile dysfunction. In: Erectile Dysfunction. Edited by . New York: Springer-Verlag1991: 104. chapt. 9. Google Scholar 10 : Comment. In: World Book of Impotence Research: Basic and Clinical. Edited by . London: Smith Jordon & Co., Ltd.1992: 194. chapt. 13. Google Scholar 11 : Intracavernous pharmacotherapy for impotence: selection of appropriate agent and dose. J. Urol., part 21993; 149: 1288. Abstract, Google Scholar 12 : Intracavernous pharmacotherapy for erectile dysfunction. In: Erectile Dysfunction. Edited by . New York: Springer-Verlag1991: 221. chapt. 19. Google Scholar 13 : Potentiation of drug-induced erection with audiovisual sexual stimulation. Urology1993; 41: 431. Google Scholar 14 : Enhanced pharmacological testing in erectile dysfunction. Int. J. Impotence Res.1994; 1: D-47. Google Scholar 15 : The combined intracavernous injection and stimulation test: diagnostic accuracy. J. Urol.1992; 148: 61. Link, Google Scholar 16 : Physiology of erection and pharmacological management of impotence. J. Urol.1987; 137: 829. Link, Google Scholar 17 : Papaverine-phentolamine and prostaglandin E1 versus papaverine-phentolamine alone for intracorporeal injection therapy: a clinical double-blind study. J. Urol.1995; 154: 1017. Abstract, Google Scholar 18 : Prostaglandin E1 versus mixture of prostaglandin E1, papaverine and phentolamine in nonresponders to high papaverine plus phentolamine doses. J. Urol.1996; 155: 913. Abstract, Google Scholar 19 : Rescuing the failed injection patient with the use of forskolin. J. Urol., part 21996; 155: 496A. abstract 743. Google Scholar 20 : Efficiency and side effects of prostaglandin E1 in the treatment of erectile dysfunction. J. Urol.1988; 140: 525. Link, Google Scholar 21 : Prostaglandin E1 versus phentolamine/papaverine for the treatment of erectile impotence: a double-blind comparison. J. Urol.1989; 141: 549. Link, Google Scholar 22 : Prostaglandin E1 therapy for impotence, comparison with papaverine. J. Urol.1990; 143: 57. Link, Google Scholar 23 : Comparison of papaverine and prostaglandin E1 (PGE1) single drug therapy for erectile dysfunction. J. Urol., part 21996; 156: 468A. abstract 631A. Google Scholar 24 : Pharmacological erection program using prostaglandin E1. J. Urol.1991; 146: 786. Link, Google Scholar 25 : Comparative value of prostaglandin E1 and papaverine in treatment of erectile failure: double-blind crossover study among Egyptian patients. J. Urol.1992; 147: 623. Link, Google Scholar 26 : Intracavernous injection therapy: analysis of results and complications. J. Urol.1990; 143: 1138. Link, Google Scholar 27 : Pharmacotherapy of impotence: where are we going?. In: World Book of Impotence Research: Basic and Clinical. Edited by . London: E. Smith Jordon & Co., Ltd.1992: 181. chapt. 13. Google Scholar 28 : Intracavernous injection of prostaglandin E1 in impotent men. J. Urol.1988; 140: 66. Link, Google Scholar 29 : Prostaglandin E1 in erectile dysfunction. Efficiency and incidence of priapism. Brit. J. Urol.1990; 65: 68. Google Scholar 30 : Local and systemic effects of chronic intracavernous injection of papaverine, prostaglandin E1, and saline in primates. J. Urol.1989; 142: 403. Link, Google Scholar 31 : Experience with an intracavernous drug delivery system. J. Urol., part 21988; 139: 328A. abstract 664. Google Scholar 32 : Vasoactive intracavernous pharmacotherapy for the treatment of erectile impotence in men with spinal cord injury. J. Urol.1987; 138: 539. Link, Google Scholar 33 : The prevalence and causes of patient drop-out from long-term self-injection therapy for impotence: survey results from 708 respondents. J. Urol., part 21996; 155: 469A. abstract 632. Google Scholar From the Urology Division, Hospital Durand, Buenos Aires, Argentina.© 1997 by American Urological Association, Inc.FiguresReferencesRelatedDetails Volume 157Issue 6June 1997Page: 2132-2134 Advertisement Copyright & Permissions© 1997 by American Urological Association, Inc.MetricsAuthor Information A. Bechara More articles by this author A. Casabe More articles by this author G. Cheliz More articles by this author S. Romano More articles by this author H. Rey More articles by this author N. Fredotovich More articles by this author Expand All Advertisement PDF downloadLoading ...
Referência(s)